An Open Trial of Guanfacine in the Treatment of Attention-Deficit Hyperactivity Disorder
- 1 January 1995
- journal article
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 34 (1), 50-54
- https://doi.org/10.1097/00004583-199501000-00013
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Catecholamine mechanisms in age-related cognitive declineNeurobiology of Aging, 1993
- Alpha-2 adrenergic agonists decrease distractibility in aged monkeys performing the delayed response taskPsychopharmacology, 1992
- Behavioral and receptor binding analysis of the α2-adrenergic agonist, 5-bromo-6 [2-imidazoline-2-YL amino] quinoxaline (UK-14304): evidence for cognitive enhancement at an α2-adrenoceptor subtypeNeuropharmacology, 1991
- Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disordersAmerican Journal of Psychiatry, 1991
- Separation of DSM-III attention deficit disorder and conduct disorder: evidence from a family-genetic study of American child psychiatric patientsPsychological Medicine, 1991
- α2‐Adrenoceptor subtypes and imidazoline‐like binding sites in the rat brainBritish Journal of Pharmacology, 1990
- The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypesJournal of Neuroscience, 1988
- α 2 -Adrenergic Mechanisms in Prefrontal Cortex Associated with Cognitive Decline in Aged Nonhuman PrimatesScience, 1985
- Factors associated with children’s adherence to stimulant medication.American Journal of Orthopsychiatry, 1982
- A Teacher Rating Scale for Use in Drug Studies with ChildrenAmerican Journal of Psychiatry, 1969